Week of June 21th 2021 | Vol. 10, Issue 26
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory
INDUSTRY M&A SNAPSHOT

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
MARKET REPORTS
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Danaher, a science and technology company, has agreed to acquire biotech firm Aldevron from EQT Private Equity for an enterprise value of $9.bn.

Established in 1998, Aldevron is headquartered in Fargo, North Dakota, US. The company produces plasmid DNA, mRNA and recombinant proteins used in vaccines, gene and cell therapy, gene editing and diagnostic applications.

Aldevron offers its products to biotechnology and pharmaceutical clients for research, clinical and commercial purposes. It supplied the plasmid DNA utilised to produce mRNA Covid-19 vaccines, EQT noted.

EQT purchased a majority stake in Aldevron in 2019, investing along with TA Associates, founders and management to aid the biotech in developing biologics.


RECENT INDUSTRY TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
19 transactions totaling $10,426 million
Supplies, Equipment & Services
23 transactions totaling $48 million
Healthcare IT & Managed Care
8 transactions
Healthcare Facilities & Distributors
22 transactions totaling $2,858 million
Pharma & Biotech
32 transactions totaling $1,510 million
Supplies, Equipment & Services
23 transactions totaling $622 million
Healthcare IT & Managed Care
9 transactions totaling $112 million
Healthcare Facilities & Distributors
2 transaction totaling $11 million
Pharma & Biotech
15 transactions totaling $8,759 million
Supplies, Equipment & Services
5 transactions totaling $75 million
Healthcare IT & Managed Care
1 transactions totaling $6 million
Healthcare Facilities & Distributors
1 transactions totaling $15 million
INDUSTRY TRADING COMPS
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
RECENT INDUSTRY TRANSACTIONS
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
June 18, 2021 - Fierce Biotech
Gilead Sciences' Kite Pharma unit made its name developing autologous CAR-T treatments made from a patient’s own cells. Now, the subsidiary is making another big play in off-the-shelf treatments that can be developed more quickly in a deal with Shoreline Biosciences that could exceed $2.3 billion.

June 17, 2021 - Pharmaceutical Business Review
Novartis has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for 177Lu-PSMA-617 to treat metastatic castration-resistant prostate cancer (mCRPC).

June 17, 2021 - Fierce Healthcare
Tenet Healthcare has sold off five Florida hospitals and their associated physician practices to Steward Health Care System for roughly $1.1 billion, the organizations announced late Wednesday.

June 17, 2021 - Contract Pharma
The newly completed $425 million investment in the facility expands production and distribution of Sanofi's Fluzone High-Dose Quadrivalent for the upcoming 2021-2022 influenza season in the U.S. and will create up to 200 additional manufacturing jobs. Commercialization activities for the U.S. market are underway, with plans to support other countries in the future.
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.